Where an SSA and cisplatin were present as a co-formulation, they have been supplied in a 1 : 1 molar ratio. For processed data please see Fig. S7–S25 (see ESI). CMC, DLS and zeta potential data were obtained for a H2O/5.0% EtOH solutions of an SSA or 1 : 1 cisplatin co-formulation (0.56 mM) at 298 K, except for CMC studies that were performed at a variety of concentrations. Quantitative 1H NMR data were obtained for a D2O/5.0% EtOH solutions of an SSA or 1 : 1 cisplatin co-formulation (5.5 mM) at 298 K. Here % values represent the proportion of compound to become NMR silent, and thus adopt solid like properties as this proportion of molecular species are incorporated into larger self-associated aggregates. All quantitative 1H NMR experiments were conducted with a delay time (d1) of 60 s. Average DH measurements were obtained from DLS intensity particle size distribution peak maxima.
| Compound | Quantitative 1H NMR (%) | Zeta potential (mV) | D H (nm) | CMC (mM) | |
|---|---|---|---|---|---|
| SSA anion | SSA cation | ||||
| 1 only | 51 (ref. 7) | 50 (ref. 7) | −67 (ref. 10) | 142 (ref. 7) | 10.4 (ref. 7) |
| 1 + cisplatin | 65 (ref. 10) | 83 (ref. 10) | −42 (ref. 10) | 161 (ref. 10) | 3.3 (ref. 10) |
| 6 only | 10 (ref. 7) | 8 (ref. 7) | −44 (ref. 10) | 300 (ref. 7) | 0.5 (ref. 7) |
| 6 + cisplatin | 63 | 85 | −53 | 240 | 2.0 |